Table 1

Measures of β-cell secretory function during hyperglycemic clamp and ratio to pretreatment in the exenatide- and insulin glargine–treated groups

Pretreatment (week −2)On-drug (week 52)Off-drug (week 56)On-drug ratio to pretreatment (week 52)
Off-drug ratio to pretreatment (week 56)
Geometric meanBetween-group differencePGeometric meanBetween-group differenceP
First phase
    Insulin glargine5.4 ± 0.66.1 ± 0.56.1 ± 0.61.17 ± 0.061.13 ± 0.05
    Exenatide5.4 ± 0.69.4 ± 1.05.0 ± 0.61.78 ± 0.111.53 ± 0.11<0.00011.00 ± 0.050.90 ± 0.060.1188
Second phase
    Insulin glargine77.4 ± 8.880.7 ± 6.986.2 ± 9.11.08 ± 0.051.10 ± 0.05
    Exenatide78.5 ± 8.3235.6 ± 23.079.5 ± 9.13.05 ± 0.222.85 ± 0.22<0.00011.01 ± 0.040.92 ± 0.060.1996
AIRarg
    Insulin glargine20.0 ± 2.524.8 ± 2.221.4 ± 2.51.31 ± 0.071.03 ± 0.08
    Exenatide19.7 ± 2.162.2 ± 7.022.0 ± 2.63.19 ± 0.242.46 ± 0.20<0.00011.12 ± 0.061.08 ± 0.100.4052
  • Data represent mean ± SEM. n = 30 in the exenatide- and insulin glargine–treated groups. Ratios from pretreatment are presented as geometric mean ± SEM. AIRarg, C-peptide response to arginine at 15 mmol/l glucose concentration (nmol · min−1 · l−1); first-phase, first-phase C-peptide response to glucose (nmol · min−1 · l−1; second-phase, second-phase C-peptide response to glucose (nmol · min−1 · l−1). See research design and methods for calculations of β-cell function measures.